Under the terms of the agreement, a newly formed wholly-owned subsidiary of Isoray will merge with and into Viewpoint, with Viewpoint continuing as the surviving corporation and a subsidiary of Isoray.
“I believe the combination of Isoray, and Viewpoint presents a unique platform company in the precision radiation therapy market,” said Viewpoint Molecular Targeting CEO Thijs Spoor. “The companies’ shared vision of treating cancer from the inside out and pioneering effective, personalized cancer-fighting therapies that aim to minimize unwanted side effects presents a compelling proposition for patients, clinicians, and investors. At Viewpoint Molecular Targeting, we believe this proposed merger brings together two innovative medical technology companies to create a dynamic new force to make cancer care more personalized.”
The merger is subject to approval by the shareholders of both Isoray and Viewpoint. The deal is expected to close by the end of this calendar year.